#1 out of 1673.75%
health1h ago
Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells
- Japan grants conditional, time-limited marketing approval to two iPS-derived regenerative products, marking a first for the field.
- ReHeart is designed for patients with severe heart failure due to ischemic cardiomyopathy and is implanted via surgery.
- Amusepri targets Parkinson’s disease and involves transplanting progenitor cells into the brain.
- Manufacturing and device development were led by SMaRT in Osaka, highlighting Japan's integrated supply chain.
- Post-approval studies will continue to verify safety and efficacy in real-world settings.
- The approvals reflect Japan's policy to enable earlier access to regenerative therapies amid complex trials.
- Kyoto University and related institutions contributed to technology development and supply.
- The program envisions insurance coverage for these products after regulatory approval.
- A comprehensive study is planned to monitor ReHeart’s outcomes in a target group of patients.
- The approvals demonstrate Japan's role in pioneering regenerative medicine globally.
Vote 0








